China Biologic Products Holdings, Inc.
CBPO
CBPO was delisted on the 20th of April, 2021.
89 hedge funds and large institutions have $1.79B invested in China Biologic Products Holdings, Inc. in 2019 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 23 increasing their positions, 25 reducing their positions, and 9 closing their positions.
200% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 9
26% more capital invested
Capital invested by funds: $1.42B → $1.79B (+$365M)
25% more funds holding
Funds holding: 71 → 89 (+18)
2.51% more ownership
Funds ownership: 38.31% → 40.82% (+2.5%)
8% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 25
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
29% less call options, than puts
Call options by funds: $22.8M | Put options by funds: $32.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$83.8M |
| 2 |
AII
AGF Investments Inc
Toronto,
Ontario, Canada
|
+$21.4M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$17.2M |
| 4 |
KLCMU
Kite Lake Capital Management (UK)
London,
United Kingdom
|
+$12M |
| 5 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$8.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$32.7M |
| 2 |
GAM
Greenwoods Asset Management
Grand Cayman,
Cayman Islands
|
-$23.8M |
| 3 |
HSBC Holdings
London,
United Kingdom
|
-$23.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$15M |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$11.4M |
CBPO Hedge Fund Activity: Q3 2019 in Review
89 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in China Biologic Products Holdings, Inc. (CBPO) for Q3 2019, worth a combined $1.79B — up 26% from $1.42B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new CBPO positions and 9 closed out — a net gain of 18 holders — while 23 added to existing stakes and 25 trimmed.
The largest buyer was Capital Research Global Investors, adding an estimated $83.8M. The largest seller was Capital World Investors, exiting entirely with an estimated $32.7M sold.
- 89 institutional investors held China Biologic Products Holdings, Inc. (CBPO) as of Q3 2019, up from 71 in Q2 2019.
- Funds reported $1.79B of China Biologic Products Holdings, Inc. stock for Q3 2019, up 26% quarter-over-quarter.
- 27 funds opened new China Biologic Products Holdings, Inc. positions in Q3 2019 and 9 closed out, a net change of +18 holders.
- The largest China Biologic Products Holdings, Inc. buyer in Q3 2019 was Capital Research Global Investors, an estimated $83.8M added.
- The largest China Biologic Products Holdings, Inc. seller in Q3 2019 was Capital World Investors, an estimated $32.7M sold.
Based on aggregated 13F filings for Q3 2019.